Medicus Pharma’s (MDCX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Medicus Pharma (NASDAQ:MDCX) in a report released on Monday morning,Benzinga reports. They currently have a $14.00 price objective on the stock.

Several other brokerages have also recently commented on MDCX. D Boral Capital upgraded shares of Medicus Pharma to a “strong-buy” rating in a research note on Monday, April 14th. Brookline Capital Management upgraded Medicus Pharma to a “strong-buy” rating in a research report on Monday, December 23rd.

Medicus Pharma Price Performance

NASDAQ:MDCX opened at $3.92 on Monday. The stock’s 50-day simple moving average is $3.58. Medicus Pharma has a 12-month low of $1.80 and a 12-month high of $6.00.

Medicus Pharma (NASDAQ:MDCX) last announced its quarterly earnings data on Friday, March 28th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.14. As a group, research analysts anticipate that Medicus Pharma will post -1.14 EPS for the current year.

Institutional Investors Weigh In On Medicus Pharma

A hedge fund recently bought a new stake in Medicus Pharma stock. Interchange Capital Partners LLC acquired a new stake in Medicus Pharma Ltd. (NASDAQ:MDCX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma comprises approximately 1.3% of Interchange Capital Partners LLC’s investment portfolio, making the stock its 15th largest position. Interchange Capital Partners LLC owned approximately 13.43% of Medicus Pharma at the end of the most recent reporting period.

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.